Is Inclisiran (Leqvio) injection medically necessary for a patient with hyperlipidemia (E78.5), history of clinical atherosclerotic cardiovascular disease (ASCVD), and either current LDL-C level ≥ 70 mg/dL or prior treatment with high-intensity statin, considering their complex medical history including obesity, history of gastric ulcer, and peptic ulcer disease?

Medical Necessity Determination: Inclisiran Injection for Hyperlipidemia

Summary Assessment

The inclisiran injection was NOT medically necessary based on the documentation provided, as the patient failed to meet the plan's coverage criteria requiring documented history of clinical ASCVD and either current LDL-C ≥70 mg/dL or prior statin trial.

---

Critical Missing Documentation

Absence of ASCVD Confirmation

• The medical record does not document a history of clinical atherosclerotic cardiovascular disease (ASCVD), which is the foundational requirement for inclisiran coverage according to the plan criteria 1
• Clinical ASCVD includes: acute coronary syndromes, history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin 2
• The patient's medical history lists breast cancer, gastric ulcer, peptic ulcer disease, obesity, and seasonal allergies—but no cardiovascular disease [@case documentation@]

Missing LDL-C Values

• No baseline LDL-C level is documented in the submitted records to verify the patient met the threshold of ≥70 mg/dL required by plan criteria [@plan criteria@]
• The office visit notes reference "Result Labs" with dates but the actual LDL-C values are redacted/missing from pages provided [@case documentation@]
• FDA labeling for inclisiran requires patients to have elevated LDL-C despite maximally tolerated statin therapy 1

Inadequate Statin Trial Documentation

• No documentation of "at least three months of treatment with a high-intensity statin" as required by plan criteria [@plan criteria@]
• While the assessment mentions "injectable cholesterol medications" discussion and plans for Leqvio, there is no evidence the patient was on or tried statin therapy [@case documentation@]
• The 2024 International Lipid Expert Panel recommends inclisiran only after maximally tolerated statin therapy plus ezetimibe if LDL-C goals are not achieved 2

---

Plan Coverage Criteria Analysis

Criteria NOT Met

Criterion 1a: History of Clinical ASCVD

• The plan requires "Member has a history of clinical atherosclerotic cardiovascular disease (ASCVD)" [@plan criteria@]
• FAILED: No ASCVD diagnosis documented in the medical history or problem list [@case documentation@]

Criterion 2a: Current LDL-C ≥70 mg/dL

• The plan requires "Member has a current LDL-C level greater than or equal to 70 mg/dL" [@plan criteria@]
• CANNOT VERIFY: LDL-C values are not provided in the submitted documentation [@case documentation@]

Criterion 3a: Prior Statin Trial

• The plan requires "Member has received at least three months of treatment with a high-intensity statin" [@plan criteria@]
• FAILED: No documentation of statin therapy trial, duration, or intolerance [@case documentation@]

Diagnosis Code Limitation

• E78.5 (Hyperlipidemia, unspecified) does not establish ASCVD and is insufficient for inclisiran coverage [@plan criteria@]
• This is a non-specific lipid disorder code that does not meet the "clinical ASCVD" requirement 2

---

Guideline-Based Medical Necessity Standards

FDA-Approved Indications

• Inclisiran is FDA-approved "as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-C" 1
• This patient's documentation does not establish either indication [@case documentation@]

Clinical Practice Guidelines

• The 2024 International Lipid Expert Panel recommends inclisiran for ASCVD patients failing to reach LDL-C goals on statin therapy, following a treatment sequence of: maximally tolerated statin → add ezetimibe → add PCSK9 inhibitor (including inclisiran) 2
• The 2018 ACC/AHA Cholesterol Guidelines recommend adding non-statin therapy (including PCSK9 inhibitors) only in very-high-risk ASCVD patients with LDL-C ≥70 mg/dL despite maximally tolerated statin therapy 2
• The patient has not progressed through this evidence-based treatment algorithm [@case documentation@]

VICTORION-INITIATE Trial Context

• The recent VICTORION-INITIATE study demonstrated an "inclisiran first" strategy achieved LDL-C <70 mg/dL in 81.8% of patients versus 22.2% with usual care 2, 3
• However, this trial enrolled patients with documented ASCVD and baseline LDL-C of 97.4 mg/dL on maximally tolerated statins—criteria not met in this case 3

---

Common Pitfalls in Inclisiran Authorization

Documentation Failures

• Failing to document specific ASCVD events (MI, stroke, revascularization, etc.) rather than just "hyperlipidemia" 4, 5
• Not providing actual LDL-C laboratory values with dates to establish baseline and on-treatment levels 4, 5, 6
• Omitting statin trial history including specific agents, doses, duration, and reasons for discontinuation or intolerance 4, 6

Premature Use

• Inclisiran should not be first-line therapy—it is reserved for patients who have failed or cannot tolerate statins 1, 7, 8
• The 2022 ACC Expert Consensus Decision Pathway recommends non-statin therapy only after maximally tolerated statin therapy plus lifestyle changes 8

---

Required Documentation for Approval

To establish medical necessity, the following must be documented:

1. Specific ASCVD diagnosis with ICD-10 codes (I21.x, I25.x, I63.x, I70.x, etc.) and clinical details of the cardiovascular event 2, 4

2. Baseline LDL-C level ≥70 mg/dL with date of laboratory test [@plan criteria@, 1]

3. Statin trial documentation including:

   • Specific statin agent and dose
   • Duration of therapy (minimum 3 months at maximally tolerated dose)
   • LDL-C response to statin therapy
   • If discontinued: specific reason (intolerance, contraindication, inadequate response) [@plan criteria@, 2]

4. Ezetimibe trial (if statin alone was inadequate) with LDL-C response 2

---

Recommendation

DENY as not medically necessary due to:

• Absence of documented clinical ASCVD
• Missing LDL-C laboratory values
• No evidence of prior statin therapy trial
• Diagnosis code E78.5 insufficient to establish ASCVD

Request additional documentation if the patient does have ASCVD and elevated LDL-C despite statin therapy, as inclisiran would then be appropriate per FDA labeling and clinical guidelines 2, 1.